The role of patient-based treatment planning in peptide receptor radionuclide therapy

[1] de Jong M(1997)Yttrium and Eur J Nucl Med 24 368-71

[2] Bakker WH(1999)Indium labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy Ann Oncol 10 S23-9

[3] Krenning EP(1997)Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy Eur J Nucl Med 24 792-5

[4] Breeman WA(2010)DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy Eur J Nucl Med Mol Imaging 37 1018-31

[5] van der Pluijm ME(2010)Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues Q J Nucl Med Mol Imaging 54 37-51

[6] Bernard BF(2011)Dosimetry for treatment with radiolabelled somatostatin analogues. A review Q J Nucl Med Mol Imaging 55 155-67

[7] Krenning EP(2013)Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy Z Med Phys 23 262-9

[8] de Jong M(2009)Treatment planning in molecular radiotherapy J Nucl Med 50 296-302

[9] Kooij PP(2002)Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model Cancer Biother Radiopharm 17 71-82

[10] Breeman WA(2013)Options for radionuclide therapy: from fixed activity to patient-specific treatment planning J Transl Med 11 17-27

[1] de Jong M(1997)Yttrium and Eur J Nucl Med 24 368-71

[2] Bakker WH(1999)Indium labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy Ann Oncol 10 S23-9

[3] Krenning EP(1997)Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy Eur J Nucl Med 24 792-5

[4] Breeman WA(2010)DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy Eur J Nucl Med Mol Imaging 37 1018-31

[5] van der Pluijm ME(2010)Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues Q J Nucl Med Mol Imaging 54 37-51

[6] Bernard BF(2011)Dosimetry for treatment with radiolabelled somatostatin analogues. A review Q J Nucl Med Mol Imaging 55 155-67

[7] Krenning EP(2013)Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy Z Med Phys 23 262-9

[8] de Jong M(2009)Treatment planning in molecular radiotherapy J Nucl Med 50 296-302

[9] Kooij PP(2002)Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model Cancer Biother Radiopharm 17 71-82

[10] Breeman WA(2013)Options for radionuclide therapy: from fixed activity to patient-specific treatment planning J Transl Med 11 17-27